Profile http://med.stanford.edu/profiles/Mark_Genovese/ Email this page Printer friendly version

Key Documents

Mark Genovese

Professor - Med Center Line, Medicine - Immunology & Rheumatology

Contact Information

Clinical Offices

Immunology & Rheumatology Clinic 300 Pasteur Dr A175 MC 5309 Stanford, CA 94305
Telephone Work (650) 723-6961 Fax (650) 725-8418

Clinical Focus

Rheumatology
Immunology/Rheumatology

Professional Education

Stanford University Medical Center (1998) CA
Stanford University Medical Center (1996) CA
Stanford University Medical Center (1995) CA
Stanford University Medical Center (1993) CA
Johns Hopkins University (1992) MD

Industry Relationships

Stanford is committed to ethical and transparent interactions with our industry partners. It is our policy to disclose payments of $5,000 or more, equity valued at $5,000 or more in a publicly traded company, or any equity in a privately held company, to physicians and scientists employed by Stanford University from companies or other commercial entities with which they interact as part of their professional activities.

Consulting: Abbott, Ardea, Biogen Idec, Horizon, Kalobios, Rigel, Synarc

Research Interests

Clinical trials and interventions in the rheumatic diseases including Rheumatoid Arthritis,Systemic Lupus Erythematosus, Systemic Sclerosis, Osteoarthritis.

Clinical Trials

Rituximab with or without Methotrexate in subjects with psoriatic arthritis and psoriasis Recruiting
Imatinib in Systemic Sclerosis Recruiting
Abatacept - IM101-158-BMS Completed

Publications

Efficacy of a p38 mitogen activated protein kinase inhibitor in mitigating an established inflammatory reaction to polyethylene particles in vivo. Ma T, Ren PG, Larsen DM, Suenaga E, Zilber S, Genovese M, Smith RL, Goodman SB. J Biomed Mater Res A. 2009; 89 (1): 117-23
First report of idiopathic granulomatous mastitis treated with methotrexate monotherapy. Schmajuk G, Genovese MC. J Rheumatol. 2009; 36 (7): 1559-60
Inhibition of p38: has the fat lady sung? Genovese MC, Arthritis Rheum. 2009; 60 (2): 317-20
Safety of biological therapies following rituximab treatment in rheumatoid arthritis patients. Genovese MC, Breedveld FC, Emery P, Cohen S, Keystone E, Matteson EL, Baptiste Y, Chai A, Burke L, Reiss W, Sweetser M, Shaw TM. Ann Rheum Dis. 2009; 68 (12): 1894-7
Less radiographic progression with adalimumab plus methotrexate versus methotrexate monotherapy across the spectrum of clinical response in early rheumatoid arthritis. Emery P, Genovese MC, van Vollenhoven R, Sharp JT, Patra K, Sasso EH. J Rheumatol. 2009; 36 (7): 1429-41
Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study. Genovese MC, McKay JD, Nasonov EL, Mysler EF, da Silva NA, Alecock E, Woodworth T, Gomez-Reino JJ. Arthritis Rheum. 2008; 58 (10): 2968-80
Efficacy and safety of the selective co-stimulation modulator abatacept following 2 years of treatment in patients with rheumatoid arthritis and an inadequate response to anti-tumour necrosis factor therapy. Genovese MC, Schiff M, Luggen M, Becker JC, Aranda R, Teng J, Li T, Schmidely N, Le Bars M, Dougados M. Ann Rheum Dis. 2008; 67 (4): 547-54
Ocrelizumab, a humanized anti-CD20 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: A phase I/II randomized, blinded, placebo-controlled, dose-ranging study. Genovese MC, Kaine JL, Lowenstein MB, Giudice JD, Baldassare A, Schechtman J, Fudman E, Kohen M, Gujrathi S, Trapp RG, Sweiss NJ, Spaniolo G, Dummer W. Arthritis Rheum. 2008; 58 (9): 2652-61
Efficacy results from pivotal clinical trials with abatacept. Rozelle AL, Genovese MC. Clin Exp Rheumatol. 2007 Sep-Oct; 25 (5 Suppl 46): S30-4
A pilot study of tumor necrosis factor inhibition in erosive/inflammatory osteoarthritis of the hands. Magnano MD, Chakravarty EF, Broudy C, Chung L, Kelman A, Hillygus J, Genovese MC. J Rheumatol. 2007; 34 (6): 1323-7
Proteomic analysis of secreted proteins in early rheumatoid arthritis: anti-citrulline autoreactivity is associated with up regulation of proinflammatory cytokines. Hueber W, Tomooka BH, Zhao X, Kidd BA, Drijfhout JW, Fries JF, van Venrooij WJ, Metzger AL, Genovese MC, Robinson WH. Ann Rheum Dis. 2007; 66 (6): 712-9
A pilot trial of rituximab in the treatment of patients with dermatomyositis. Chung L, Genovese MC, Fiorentino DF. Arch Dermatol. 2007; 143 (6): 763-7
Safety and efficacy of adalimumab in treatment of patients with psoriatic arthritis who had failed disease modifying antirheumatic drug therapy. Genovese MC, Mease PJ, Thomson GT, Kivitz AJ, Perdok RJ, Weinberg MA, Medich J, Sasso EH. J Rheumatol. 2007; 34 (5): 1040-50
Selective tyrosine kinase inhibition by imatinib mesylate for the treatment of autoimmune arthritis. Paniagua RT, Sharpe O, Ho PP, Chan SM, Chang A, Higgins JP, Tomooka BH, Thomas FM, Song JJ, Goodman SB, Lee DM, Genovese MC, Utz PJ, Steinman L, Robinson WH. J Clin Invest. 2006; 116 (10): 2633-42
Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition. Genovese MC, Becker JC, Schiff M, Luggen M, Sherrer Y, Kremer J, Birbara C, Box J, Natarajan K, Nuamah I, Li T, Aranda R, Hagerty DT, Dougados M. N Engl J Med. 2005; 353 (11): 1114-23
A randomized, blinded, parallel group, placebo controlled pilot study evaluating the effect of PVAC treatment in patients with diffuse systemic sclerosis. Genovese MC, Chakravarty EF, Boyle DL, Tutuncu Z, Thorburn CM, Halilhodzic M, Kroll S, Baughman J, Stewart S, Kavanaugh A. J Rheumatol. 2005; 32 (12): 2345-50
Biologic therapies in clinical development for the treatment of rheumatoid arthritis. Genovese MC, J Clin Rheumatol. 2005; 11 (3 Suppl): S45-54
Longterm safety, efficacy, and radiographic outcome with etanercept treatment in patients with early rheumatoid arthritis. Genovese MC, Bathon JM, Fleischmann RM, Moreland LW, Martin RW, Whitmore JB, Tsuji WH, Leff JA. J Rheumatol. 2005; 32 (7): 1232-42
Antigen microarray profiling of autoantibodies in rheumatoid arthritis. Hueber W, Kidd BA, Tomooka BH, Lee BJ, Bruce B, Fries JF, Sønderstrup G, Monach P, Drijfhout JW, van Venrooij WJ, Utz PJ, Genovese MC, Robinson WH. Arthritis Rheum. 2005; 52 (9): 2645-55
Factors that predict prematurity and preeclampsia in pregnancies that are complicated by systemic lupus erythematosus. Chakravarty EF, Colón I, Langen ES, Nix DA, El-Sayed YY, Genovese MC, Druzin ML. Am J Obstet Gynecol. 2005; 192 (6): 1897-904
Management of co-morbidities and general medical conditions in patients with rheumatoid arthritis. Magnano MD, Genovese MC. Curr Rheumatol Rep. 2005; 7 (5): 407-15
Temporal effects of a COX-2-selective NSAID on bone ingrowth. Goodman SB, Ma T, Mitsunaga L, Miyanishi K, Genovese MC, Smith RL. J Biomed Mater Res A. 2005; 72 (3): 279-87
Pharmacologic modulation of periprosthetic osteolysis. Goodman SB, Trindade M, Ma T, Genovese M, Smith RL. Clin Orthop Relat Res. 2005; (430): 39-45
A randomized, controlled trial of interferon-beta-1a (Avonex(R)) in patients with rheumatoid arthritis: a pilot study [ISRCTN03626626]. Genovese MC, Chakravarty EF, Krishnan E, Moreland LW. Arthritis Res Ther. 2004; 6 (1): R73-R77
Unlocking the "PAD" lock on rheumatoid arthritis. Utz PJ, Genovese MC, Robinson WH. Ann Rheum Dis. 2004; 63 (4): 330-2
Combination therapy with etanercept and anakinra in the treatment of patients with rheumatoid arthritis who have been treated unsuccessfully with methotrexate. Genovese MC, Cohen S, Moreland L, Lium D, Robbins S, Newmark R, Bekker P. Arthritis Rheum. 2004; 50 (5): 1412-9
Treatment of rheumatoid arthritis with etanercept. Genovese MC, Kremer JM. Rheum Dis Clin North Am. 2004; 30 (2): 311-28, vi-vii
Associations between rheumatoid arthritis and malignancy. Chakravarty EF, Genovese MC. Rheum Dis Clin North Am. 2004; 30 (2): 271-84, vi
COX-2 selective inhibitors and bone. Goodman SB, Ma T, Genovese M, Lane Smith R. Int J Immunopathol Pharmacol. 2003 Sep-Dec; 16 (3): 201-5
Interleukin 1 receptor antagonist inhibits localized bone formation in vivo. Ma T, Miyanishi K, Trindade MC, Genovese M, Regula D, Smith RL, Goodman SB. J Rheumatol. 2003; 30 (12): 2547-52
Imaging of the articular cartilage in osteoarthritis of the knee joint: 3D spatial-spectral spoiled gradient-echo vs. fat-suppressed 3D spoiled gradient-echo MR imaging. Yoshioka H, Alley M, Steines D, Stevens K, Rubesova E, Genovese M, Dillingham MF, Lang P. J Magn Reson Imaging. 2003; 18 (1): 66-71
Modulation of bone ingrowth and tissue differentiation by local infusion of interleukin-10 in the presence of ultra-high molecular weight polyethylene (UHMWPE) wear particles. Goodman S, Trindade M, Ma T, Lee M, Wang N, Ikenou T, Matsuura I, Miyanishi K, Fox N, Regula D, Genovese M, Klein J, Bloch D, Smith RL. J Biomed Mater Res A. 2003; 65 (1): 43-50
Rheumatic syndromes associated with malignancy. Chakravarty E, Genovese MC. Curr Opin Rheumatol. 2003; 15 (1): 35-43
Expression of the chemokine receptors CCR4, CCR5, and CXCR3 by human tissue-infiltrating lymphocytes. Kunkel EJ, Boisvert J, Murphy K, Vierra MA, Genovese MC, Wardlaw AJ, Greenberg HB, Hodge MR, Wu L, Butcher EC, Campbell JJ. Am J Pathol. 2002; 160 (1): 347-55
COX-2 selective NSAID decreases bone ingrowth in vivo. Goodman S, Ma T, Trindade M, Ikenoue T, Matsuura I, Wong N, Fox N, Genovese M, Regula D, Smith RL. J Orthop Res. 2002; 20 (6): 1164-9
Central nervous system lupus and pregnancy: 11-year experience at a single center. El-Sayed YY, Lu EJ, Genovese MC, Lambert RE, Chitkara U, Druzin ML. J Matern Fetal Neonatal Med. 2002; 12 (2): 99-103
Etanercept versus methotrexate in patients with early rheumatoid arthritis: two-year radiographic and clinical outcomes. Genovese MC, Bathon JM, Martin RW, Fleischmann RM, Tesser JR, Schiff MH, Keystone EC, Wasko MC, Moreland LW, Weaver AL, Markenson J, Cannon GW, Spencer-Green G, Finck BK. Arthritis Rheum. 2002; 46 (6): 1443-50
Long-term followup of patients treated with total lymphoid irradiation for lupus nephritis. Genovese MC, Uhrin Z, Bloch DA, Oehlert J, Sibley RK, Myers B, Strober S. Arthritis Rheum. 2002; 46 (4): 1014-8
Autoantigen microarrays for multiplex characterization of autoantibody responses. Robinson WH, DiGennaro C, Hueber W, Haab BB, Kamachi M, Dean EJ, Fournel S, Fong D, Genovese MC, de Vegvar HE, Skriner K, Hirschberg DL, Morris RI, Muller S, Pruijn GJ, van Venrooij WJ, Smolen JS, Brown PO, Steinman L, Utz PJ. Nat Med. 2002; 8 (3): 295-301
Current management of rheumatoid arthritis. Genovese MC, Davis JS. Hosp Pract (Minneap). 2001; 36 (2): 21-6, 29-30, 35
Bonzo/CXCR6 expression defines type 1-polarized T-cell subsets with extralymphoid tissue homing potential. Kim CH, Kunkel EJ, Boisvert J, Johnston B, Campbell JJ, Genovese MC, Greenberg HB, Butcher EC. J Clin Invest. 2001; 107 (5): 595-601
Demyelinating and neurologic events reported in association with tumor necrosis factor alpha antagonism: by what mechanisms could tumor necrosis factor alpha antagonists improve rheumatoid arthritis but exacerbate multiple sclerosis? Robinson WH, Genovese MC, Moreland LW. Arthritis Rheum. 2001; 44 (9): 1977-83
Rules of chemokine receptor association with T cell polarization in vivo. Kim CH, Rott L, Kunkel EJ, Genovese MC, Andrew DP, Wu L, Butcher EC. J Clin Invest. 2001; 108 (9): 1331-9
Treatment of rheumatoid arthritis with total lymphoid irradiation: long-term survival. Uhrin Z, Wang BW, Matsuda Y, Strober S, Genovese MC. Arthritis Rheum. 2001; 44 (7): 1525-8
Lymphocyte CC chemokine receptor 9 and epithelial thymus-expressed chemokine (TECK) expression distinguish the small intestinal immune compartment: Epithelial expression of tissue-specific chemokines as an organizing principle in regional immunity. Kunkel EJ, Campbell JJ, Haraldsen G, Pan J, Boisvert J, Roberts AI, Ebert EC, Vierra MA, Goodman SB, Genovese MC, Wardlaw AJ, Greenberg HB, Parker CM, Butcher EC, Andrew DP, Agace WW. J Exp Med. 2000; 192 (5): 761-8
A novel chemokine ligand for CCR10 and CCR3 expressed by epithelial cells in mucosal tissues. Pan J, Kunkel EJ, Gosslar U, Lazarus N, Langdon P, Broadwell K, Vierra MA, Genovese MC, Butcher EC, Soler D. J Immunol. 2000; 165 (6): 2943-9
A double-blind, placebo-controlled, clinical trial of dehydroepiandrosterone in severe systemic lupus erythematosus. van Vollenhoven RF, Park JL, Genovese MC, West JP, McGuire JL. Lupus. 1999; 8 (3): 181-7
Joint and soft-tissue injection. A useful adjuvant to systemic and local treatment. Genovese MC, Postgrad Med. 1998; 103 (2): 125-34
Fever, rash, and arthritis in a woman with silicone gel breast implants. Genovese MC, West J Med. 1997; 167 (3): 149-58
Lemierre's syndrome. Lee BK, Lopez F, Genovese M, Loutit JS. South Med J. 1997; 90 (6): 640-3